Back to results
US 4,537,768 AGranted
Combined vaccine
AssigneeRoussel Uclaf
InventorsPeter Apontoweil, Johannes A. G. Kok
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRoussel Uclaf
InventorsPeter Apontoweil, Johannes A. G. Kok
Estimating the term…
Combined, inactivated vaccine ready for administration and active against at least Newcastle disease and egg production drop caused by adeno-like viruses and process for the preparation of such vaccine by addition of (A) a Newcastle disease virus (NDV) containing liquid obtained by cultivation of a NDV, followed by inactivation of the liquid and optionally homogenizing it, together with (B) an adeno-like virus (ALV) containing liquid obtained by cultivation of an ALV, followed by inactivation of the liquid and optionally homogenizing it, to an oil phase containing as essential components at least one of the components selected from the group consisting of light paraffinic mineral oils, vegetable oils and naphtenic mineral oils and one or more emulsifiers such as nonionic surface-active compounds derived from alkylene oxide and/or hexahydric alcohols and/or higher natural fatty acids such as esters or ester-ethers, optionally followed by homogenizing and/or addition of a preservative.
In a combined inactivated vaccine ready for administration and active against Newcastle disease and egg production drop comprising a mixture of an aqueous phase containing an inactivated adeno-like virus (ALV) and an inactivated Newcastle disease virus (NDV) and an oily phase containing at least one emulsifier, the improvement, resulting in a smaller volume for administration, thus causing less irritation, comprising the aqueous phase comprising an adeno-like virus (ALV) containing aqueous liquid obtained by cultivating an in duck egg passaged virus strain 127 with a titre of at least 4.times.10.sup.2 units/ml and an aqueous liquid of an inactivated Newcastle disease virus (NDV) with a titre of at least 10.sup.9.8 EID.sub.50 /ml, the volume ratio of NDV-liquid and ALV liquid being 3:4 to 5:1 and the volume ratio between the aqueous phase containing both virus liquids and the oily phase being 7:13 to 3:7.
Dependencies are inferred from the claim text.